Sign In
Buy AIMT
$34.49
+0 (+0%)
At Close: May 27, 2022
Aimmune Therapeutics (AIMT) Gets a Buy Rating from Wedbush
10:16am, Friday, 24'th Apr 2020
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Aimmune Therapeutics (AIMT – Research Report),
Aimmune: Current Lows Look Attractive, But Coronavirus May Play Spoilsport
02:42pm, Thursday, 23'rd Apr 2020
AIMT is currently near its 52-week lows after Palforzia's approval. The bullish view differs with the bearish one on the commercial potentia issue. Here I weigh
Aimmune Therapeutics (NASDAQ:AIMT) Rating Lowered to Hold at Zacks Investment Research
06:10am, Thursday, 23'rd Apr 2020
Aimmune Therapeutics (NASDAQ:AIMT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports. According to Zacks, �
Zacks Investment Research Upgrades Aimmune Therapeutics (NASDAQ:AIMT) to Buy
07:50am, Wednesday, 22'nd Apr 2020
Aimmune Therapeutics (NASDAQ:AIMT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Monday, Zacks.com reports. The firm currently h
$1.75 Million in Sales Expected for Aimmune Therapeutics Inc (NASDAQ:AIMT) This Quarter
07:06am, Wednesday, 22'nd Apr 2020
Analysts expect that Aimmune Therapeutics Inc (NASDAQ:AIMT) will report $1.75 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for A
RBC Capital Keeps a Buy Rating on Alexion Pharmaceuticals (ALXN)
01:35pm, Monday, 20'th Apr 2020
In a report released today, Kennen MacKay from RBC Capital maintained a Buy rating on Alexion Pharmaceuticals (ALXN), with a price target of $136.00. The
RBC Capital Keeps a Buy Rating on Alexion Pharmaceuticals (ALXN)
01:35pm, Monday, 20'th Apr 2020
In a report released today, Kennen MacKay from RBC Capital maintained a Buy rating on Alexion Pharmaceuticals (ALXN – Research
493,939 Shares in Aimmune Therapeutics Inc (NASDAQ:AIMT) Bought by Norges Bank
10:50am, Monday, 20'th Apr 2020
Norges Bank purchased a new position in Aimmune Therapeutics Inc (NASDAQ:AIMT) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commis
Arden Trust Co Makes New $113,000 Investment in Aimmune Therapeutics Inc (NASDAQ:AIMT)
08:50am, Sunday, 19'th Apr 2020
Arden Trust Co bought a new position in Aimmune Therapeutics Inc (NASDAQ:AIMT) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 7,831 sha
Is Aimmune Therapeutics a Buy?
11:09am, Friday, 17'th Apr 2020
A recent drug approval, a competitor's setback, and a discounted stock price make Aimmune an intriguing investment.
Aimmune Therapeutics Inc (NASDAQ:AIMT) Short Interest Up 8.9% in March
06:26am, Friday, 17'th Apr 2020
Aimmune Therapeutics Inc (NASDAQ:AIMT) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 15,470,000 shares, a growth of 8.9% fr
A Tale of 2 Biotechs With Competing Peanut Allergy Treatments
06:43pm, Thursday, 16'th Apr 2020
DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist.
Geode Capital Management LLC Purchases 43,869 Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT)
09:42am, Thursday, 16'th Apr 2020
Geode Capital Management LLC grew its stake in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) by 7.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional inve
Should You Buy These 4 Biotech Stocks With Recent Drug Approvals?
10:45am, Wednesday, 15'th Apr 2020
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.
DBV Technologies: Don't Panic - The Good, The Bad, And The Opportunity
04:44pm, Tuesday, 14'th Apr 2020
DBV Technologies' stock has taken another massive hit due to managerial missteps. Their May 15 AdComm meeting was delayed after the FDA identified questions abo
